Skip to main content
. 2022 Nov 25;55(1):81–90. doi: 10.3724/abbs.2022176

Figure 6 .


Figure 6

Knockdown of DUXAP10 reverses acquired resistance to gefitinib in vivo

(A) PC9/GR cells treated with PC9/GR/sh-DUXAP10 or PC9/GR/Empty vector cells were injected into nude mice. After tumorigenesis, the mice were treated with gefitinib (10 mg/kg) by gavage. (B) Tumor weight was measured after inoculation. (C) Tumor volumes were calculated every 3 days. (D) qRT-PCR was used to detect the relative expression of DUXAP10 in the xenograft tumors ( n=7). (E) Immunostaining of OAS2 and Ki-67 expressions in representative tumors derived from PC9/GR/sh-DUXAP10 or PC9/GR/empty vector cells treated with gefitinib. Scale bar: 100 μm. (F) qRT-PCR analysis of the relative expression of DUXAP10 in gefitinib-resistant tissues before and after treatment. (G) OAS2 was detected by qRT-PCR in gefitinib-resistant tissues before and after treatment. * P<0.05, ** P<0.01.

HHS Vulnerability Disclosure